key: cord-1011039-nuwkeruy
authors: Perez-Alba, Eduardo; Nuzzolo-Shihadeh, Laura; Aguirre-Garcia, Gloria Mayela; Espinosa-Mora, Jaime; Lecona-Garcia, Juan Diego; Flores-Perez, Romulo Omar; Mendoza-Garza, Marisela; Camacho-Ortiz, Adrián
title: Baricitinib plus dexamethasone compared to dexamethasone for the treatment of severe COVID- 19 pneumonia: a retrospective analysis
date: 2021-07-03
journal: J Microbiol Immunol Infect
DOI: 10.1016/j.jmii.2021.05.009
sha: b3fe893388489a4c091e547a033891cf0a6e1eaa
doc_id: 1011039
cord_uid: nuwkeruy

Objective We aimed to analyze clinical outcomes from patients with severe COVID-19 pneumonia that received either baricitinib plus dexamethasone or dexamethasone monotherapy. Methodology We performed a retrospective comparative study. Data from hospitalized patients with severe COVID-19 pneumonia (saturation <93%, bilateral pulmonary infiltrates) that were treated with baricitinib plus dexamethasone or dexamethasone were collected. Our primary objective was to compare overall mortality and secondly to compare progression to mechanical ventilation and over infection rates. Results A total of 793 patients were assessed for inclusion criteria, 596 were excluded and 197 were analyzed for primary outcome: 123 in the baricitinib plus dexamethasone group and 74 in the dexamethasone monotherapy group. The mean age was 59.9 years (SD ± 14.5) and 62.1% (123/197) were male. 42.9% (85/197) of the cases required ICU admission and 25.8% (51/197) underwent invasive mechanical ventilation (IMV). Overall thirty-day mortality was 27.9% (55/197); Mortality was significantly lower in the baricitinib plus dexamethasone group compared to the dexamethasone monotherapy group (20.3% vs 40.5%, P=<.05). There was no difference in hospital acquired infections between both groups. Conclusion Thirty-day mortality was significantly lower in patients with COVID-19 pneumonia treated with baricitinib plus dexamethasone versus dexamethasone monotherapy. No difference was observed in progression to invasive mechanical ventilation and hospital acquired infections.

The Coronavirus disease 2019 pandemic is an ongoing and relapsing epidemiologic phenomenon that has resulted in over one million deaths worldwide. 1 Efforts in finding an adequate universal therapy such as hydroxychloroquine 2 , lopinavir/ritonavir 3 and convalescent plasma 4 have fallen short. The use of dexamethasone in patients with COVID-19 pneumonia who require supplementary oxygen is associated with lower 28-day mortality; the highest efficacy of dexamethasone was noticeable in patients requiring intubation and mechanical ventilation, while in patients requiring low-to high-flow oxygen the effect was less pronounced in the RECOVERY Collaborative Group, 2020. Remdesivir showed clinical improvement in the ACT-1 trial (Beigel J, 2020) and recently tocilizumab (RECOVERY Collaborative Group, 2021) have shown to improve outcomes in COVID-19 pneumonia patients.

Baricitinib is a Janus-associated tyrosine kinase (JAK) 1 and JAK 2 inhibitor. It modulates the immune response by regulating overactive signaling through the Janus kinase/signal transducers and activators of transcription (JAK-STAT) pathway. (Praveen et al., 2020) Furthermore, baricitinib has the advantage of providing in vitro antiviral activity at concentrations achieved with approved dosing. Therefore, it could be an attractive strategy to modulate the immunopathologic mechanisms caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (Stebbing et al., 2020) . The effects of baricitinib on the J o u r n a l P r e -p r o o f immune system in patients with COVID-19 have been explored showing promising data (Bronte V, 2020) Two small studies have explored the use of baricitinib for COVID-19 pneumonia, both combining it with lopinavir/ritonavir or hydroxychloroquine with no sufficient power to demonstrate difference in outcome (Cantini et al., 2020; Titanji et al., 2020) . The largest trial to date was the ACTT-2 study where the combination of remdesivir and baricitinib met the primary endpoint of reduction in time to recovery as compared with remdesivir monotherapy . In this work, we aimed to study patient's outcomes using dexamethasone and baricitinib compared to dexamethasone monotherapy for the treatment of moderate and severe COVID-19 pneumonia.

The university hospital "Dr José Eleuterio Gonzalez" in Monterrey, Mexico is a multi-building complex that includes two separate hospitals. The main building is a 600-bed hospital designated for the treatment of non-COVID-19 cases. The second building is a 76-bed hospital designated for the diagnosis and treatment of suspected or confirmed COVID-19 cases. All patients with respiratory symptoms compatible with COVID-19 are directed to the latter by a pre-arrival or pre-hospital triage located in the former unit.

J o u r n a l P r e -p r o o f We collected data from patients with confirmed COVID-19 hospitalized in our unit from March 2020 through November 2020. We included patients aged > 18 years, with a positive RT-PCR for SARS-CoV-2, supplemental oxygen requirement, and abnormal chest imaging that received either baricitinib plus dexamethasone or dexamethasone monotherapy. Severe COVID-19 pneumonia was defined as dyspnea, with at least one of the following: a respiratory rate of 30 or more breaths per minute, a blood oxygen saturation of 93% or less, a ratio of the partial pressure of arterial oxygen to the fraction of inspired oxygen (Pao2/Fio2) of less than 300 mm Hg, or pulmonary infiltrates in more than 50% of the lung fields (Berlin DA et al , 2020) .

We excluded patients with a hospital stay less than 24 hours, patients without oxygen requirement or patients that received any other therapies such as convalescent plasma, tocilizumab, remdesivir or methylprednisolone.

All patients received enoxaparin 1mg/kg once a day if D-dimer was <1000 ng/mL and every 12 hours if it was higher unless otherwise contraindicated. Dexamethasone was administered at a dose of 6mg IV every 24 hours for ten days. Baricitinib was started at a dose of 4 mg/day if glomerular filtration rate (GFR) was >60ml/min/1.73m2, 2 mg/day if between 30-59 ml/min/1.73m2, and it was withheld if GFR <30 ml/min/1.73m2. Baricitinib was stopped after 14 days of treatment or at discharge, whichever was first. Standard of care in our center included enoxaparin, dexamethasone as described above and baricitinib could be added J o u r n a l P r e -p r o o f at the discretion of the patient's clinician. The analysis of the data was performed in a blinded matter.

Demographic and clinical characteristics were analyzed using measures of central tendency. Warning Score (NEWS) amongst admitted patients was 6 (IQR 4 -8), which was lower in the dexamethasone monotherapy group, although not statistically significant (P=.27) (see Table 1 ). 

The current study showed that patients receiving baricitinib plus dexamethasone for moderate and severe COVID-19 pneumonia were associated with lower mortality compared to those receiving dexamethasone monotherapy. 

It is likely that indication bias favored the dexamethasone only arm, as evidenced by the lower NEWS score and ferritin concentrations (although the difference was not statistically significant) in that group; sicker patients would be given both drugs (or have a second drug added to the first) therefore, these findings are counter to what might be expected if the two strategies did not differ.

The baricitinib/dexamethasone arm had an average of two additional hospital days and was associated with greater need for critical care (the latter was not statistically significant). Our findings show that the addition of baricitinib to a dexamethasone standard treatment was associated with significantly less 30-day all-cause mortality when compared to dexamethasone alone, these differences could be influenced by the fact that more patients with ESRD on RRT were in the dexamethasone monotherapy group. Renal insufficiency and sepsis were associated more frequently at the time of death in the dexamethasone group.

The lack of difference in progression to mechanical ventilation between groups coupled with a lower overall mortality in the baricitinib plus dexamethasone group supports clinical benefit of this combination in our study population and promotes further clinical trials assessing this therapy including those that are currently recruiting patients (NCT04421027).

Adding baricitinib to dexamethasone does not appear to significantly increase infection risk, our findings showed that overall breakthrough infections were in fact les frequent compared to patients treated with dexamethasone. This is similar to the safety profile already known from long-term treatment in rheumatoid arthritis where the incidence rate of serious infection was 2.8/100 patient-years and stable over time. (Genovese et al., 2020) J o u r n a l P r e -p r o o f Limitations to our data include the absence of randomization, the retrospective nature of the study, and the fact that baricitinib was not used in patients with less than 30ml/min GFR. We did not perform follow-up after hospital discharge for late mortality assessment, and although the primary objective was 30-day mortality information regarding infection rates and survival after hospital discharge would have added valuable information. We conclude that in our study thirty-day mortality was significantly lower in patients with COVID-19 pneumonia treated with baricitinib plus dexamethasone versus dexamethasone monotherapy without a difference in progression to invasive mechanical ventilation and hospital acquired infections. .79

Lymphocytes (x10 9 /L), median (IQR) .05

Others, n (%) 7 (3. --Baricitinib plus dexamethasone --Dexamethasone monotherapy Log-rank test, P < .01

Survival Probability

WHO Coronavirus Disease (COVID-19) Dashboard | WHO Coronavirus Disease (COVID-19) Dashboard. n.d

Dexamethasone in Hospitalized Patients with Covid-19 -Preliminary Report

A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19

A Randomized Trial of Convalescent Plasma in Covid-19 Severe Pneumonia

ACTT-1 Study Group Members. Remdesivir for the Treatment of Covid-19 -Final Report

Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): preliminary results of a randomised, controlled, open-label

Janus kinase inhibitor baricitinib is not an ideal option for management of COVID-19

COVID-19: combining antiviral and anti-inflammatory treatments

Baricitinib restrains the immune dysregulation in patients with severe COVID-19

Baricitinib therapy in COVID-19: A pilot study on safety and clinical impact

Use of Baricitinib in Patients With Moderate to Severe Coronavirus Disease

Baricitinib plus Remdesivir for the Treatment of Hospitalized Adults with Covid-19. A Randomized Double-Blind Placebo-Controlled Trial

Severe Covid-19

WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group

Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19: A Meta-analysis

Effect of Dexamethasone on Days Alive and Ventilator-Free in Patients With Moderate or Severe Acute Respiratory Distress Syndrome and COVID-19: The CoDEX Randomized Clinical Trial

Safety profile of baricitinib for the treatment of rheumatoid arthritis over a median of 3 years of treatment: an updated integrated safety analysis

Baricitinib improves respiratory function in patients treated with corticosteroids for SARS-CoV-2 pneumonia: an observational cohort study n

Baricitinib as potential treatment for 2019-nCoV acute respiratory disease

Inhibition as a New Treatment Strategy for Patients with COVID-19

Mechanism of baricitinib supports artificial intelligence

JAK inhibition reduces SARS-CoV-2 liver infectivity and modulates inflammatory responses to reduce morbidity and mortality. Sci Adv

Creatinine (mg/dL), median (IQR)

AST (IU/L), median (IQR)

Troponin (ng/mL), median (IQR)

Fibrinogen (mg/dL), mean (SD)

ALT: alanine aminotransferase, AST: aspartate aminotransferase, CPK: creatinine phosphokinase, IQR: interquartile range, LDH: lactate dehydrogenase, SD: standard deviation